Venus Remedies Reports Negative Financial Performance in Q2 2024, Cash Reserves Improve

Venus Remedies, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Strong Sell' rating by MarketsMOJO.

According to the financial report, Venus Remedies has seen a negative performance in the second quarter of the fiscal year 2024-2025. The company's score has fallen from 9 to -13 in the last three months.

However, there are some positive aspects in the company's financials. The cash and cash equivalents have shown an improvement, with the highest amount of Rs 78.43 crore in the last six half-yearly periods. This indicates that the company's short-term liquidity is improving.

On the other hand, there are some areas that are not working in favor of Venus Remedies. The Profit Before Tax less Other Income (PBT) has fallen by -113.37% year on year, with a value of Rs -1.51 crore in the current quarter. The Profit After Tax (PAT) has also shown a negative trend, with a fall of -64.7% year on year.

The company's operating profit (PBDIT) has also decreased, with the lowest value of Rs 4.92 crore in the last five quarters. The operating profit margin has also hit a low of 2.94%, indicating a deterioration in the company's efficiency.

Moreover, the company's income from non-business activities is high, with non-operating income being 116.65% of the Profit Before Tax (PBT). This may not be a sustainable business model for the company. Additionally, the non-operating income has increased to Rs 10.58 crore in the last five quarters, which may not be sustainable in the long run.

Overall, Venus Remedies has shown a negative financial performance in the current quarter, with some areas of improvement and some areas of concern. Investors are advised to carefully consider these factors before making any investment decisions.